文献速递性腺与生殖内分泌肥胖与代谢综合征

超越早发性卵巢功能不全:青少年和年轻成人癌症幸存者生殖衰老分期

Beyond Premature Ovarian Insufficiency: Staging Reproductive Aging in Adolescent and Young Adult Cancer Survivors.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究在338例青少年和年轻成人癌症幸存者中评估STRAW+10标准(结合出血模式与内分泌标志物)的适用性。性腺毒性治疗与更晚期生殖衰老阶段相关。仅凭出血模式可能误判分期,提示需为这一人群修订分期标准。

要点

  • 性腺毒性治疗与更晚期的生殖衰老阶段相关。
  • 仅用出血模式而不结合内分泌标志物,可能将幸存者误判为更早或更晚的阶段。

核心结论

  • 性腺毒性治疗与更晚期生殖衰老阶段存在新关联。
  • 不结合内分泌标志物时,仅凭出血模式可将青少年和年轻成人癌症幸存者误判为更早或更晚的阶段。
  • 较大比例的幸存者其内分泌标志物与出血模式组合不符合STRAW+10标准,提示需为该人群修订分期。

研究设计与样本

  • 研究为来自Reproductive Window Study队列的样本(n=338)的横断面分析。
  • 使用月经出血数据及干血斑测定抗苗勒管激素(AMH)和促卵泡激素(FSH)进行生殖衰老分期评估。
  • 癌症治疗数据从病历中提取。

主要发现

  • 参与者平均年龄34.0±4.5岁,距癌症治疗平均6.9±4.6年。
  • 最常见癌症为淋巴瘤(31%)、乳腺癌(23%)和甲状腺癌(17%)。
  • 多数无法分类者的出血模式符合绝经过渡期,但AMH和/或FSH处于生殖期水平。
  • 可分类者中48%为峰值生殖期、30%为晚期生殖期、12%为早期过渡期、3%为晚期过渡期、7%为绝经后期;内分泌标志物可区分生殖期和过渡期内的峰值、早期和晚期阶段。

关键数值与推荐

  • 可分类幸存者的分期构成:峰值生殖期48%、晚期生殖期30%、早期过渡期12%、晚期过渡期3%、绝经后期7%。

临床怎么用

  • 对青少年和年轻成人癌症幸存者评估生殖衰老时,应结合AMH、FSH等内分泌标志物,不能仅依赖出血模式。
  • 对有性腺毒性治疗史者应关注更晚期生殖衰老阶段的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Although stages of reproductive aging for women in the general population are well described by STRAW+10 criteria, this is largely unknown for female adolescent and young adult cancer survivors (AYA survivors). OBJECTIVE: This work aimed to evaluate applying STRAW + 10 criteria in AYA survivors using bleeding patterns with and without endocrine biomarkers, and to assess how cancer treatment gonadotoxicity is related to reproductive aging stage. DESIGN: The sample (n = 338) included AYA survivors from the Reproductive Window Study cohort. Menstrual bleeding data and dried-blood spots for antimüllerian hormone (AMH) and follicle-stimulating hormone (FSH) measurements (Ansh DBS enzyme-linked immunosorbent assays) were used for reproductive aging stage assessment. Cancer treatment data were abstracted from medical records. RESULTS: Among participants, mean age 34.0 ± 4.5 years and at a mean of 6.9 ± 4.6 years since cancer treatment, the most common cancers were lymphomas (31%), breast (23%), and thyroid (17%). Twenty-nine percent were unclassifiable by STRAW + 10 criteria, occurring more frequently in the first 2 years from treatment. Most unclassifiable survivors exhibited bleeding patterns consistent with the menopausal transition, but had reproductive phase AMH and/or FSH levels. For classifiable survivors (48% peak reproductive, 30% late reproductive, 12% early transition, 3% late transition, and 7% postmenopause), endocrine biomarkers distinguished among peak, early, and late stages within the reproductive and transition phases. Gonadotoxic treatments were associated with more advanced stages. CONCLUSIONS: We demonstrate a novel association between gonadotoxic treatments and advanced stages of reproductive aging. Without endocrine biomarkers, bleeding pattern alone can misclassify AYA survivors into more or less advanced stages. Moreover, a large proportion of AYA survivors exhibited combinations of endocrine biomarkers and bleeding patterns that do not fit the STRAW + 10 criteria, suggesting the need for modified staging for this population.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Medica ACO, Whitcomb BW, Shliakhsitsava K, et al. Beyond Premature Ovarian Insufficiency: Staging Reproductive Aging in Adolescent and Young Adult Cancer Survivors. J Clin Endocrinol Metab. 2021. PMID: 33141175. doi:10.1210/clinem/dgaa797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。